natgillin/translations-raw huggingface dataset:
In the insulin degludec + liraglutide arm, the insulin dose was reduced by 20% in order to minimize the risk of hypoglycaemia.
U skupini liječenoj degludek inzulinom+liraglutidom doza inzulina smanjena je za 20% kako bi se smanjio rizik od hipoglikemije.
Self-monitoring of blood glucose is not needed in order to adjust the dose of Victoza.
Nije potrebno samopraćenje glukoze u krvi radi prilagođavanja doze lijeka Victoza.
Atorvastatin Cmax was decreased by 38% and median tmax was delayed from 1 h to 3 h with liraglutide.
Cmax atorvastatina smanjio se za 38%, dok je medijan tmax bio odgođen sa 1 h na 3 h uz liraglutid.
Liraglutide should therefore be used with caution in these patients.
Stoga je potreban oprez kod primjene liraglutida u tih bolesnika.
Cartridge (type 1 glass) with a plunger (bromobutyl) and a laminate rubber sheet (bromobutyl/polyisoprene) contained in a pre-filled multidose disposable pen made of polyolefin and polyacetal.
Uložak (staklo tipa 1) s klipom (brombutil) i pokrovom od laminirane gume (brombutil/poliizopren) nalazi se u jednokratnoj, višedoznoj napunjenoj brizgalici koja je načinjena od poliolefina i poliacetala.
OTHER SPECIAL WARNINGS, IF NECESSARY
OD LIJEKA, AKO JE POTREBNO
Addition of liraglutide resulted in a statistically significantly greater reduction of HbA1c (-0.73% for liraglutide vs -0.40% for comparator) and body weight (-3.03 vs 0.72 kg).
Dodatak liraglutida rezultirao je statistički značajno većim smanjenjem HbA1c (-0,73% za liraglutid naspram -0,40% za lijek usporedbe) i tjelesne težine (-3,03 naspram 0,72 kg).
Liraglutide exposure was lowered by 33%, 14%, 27% and 26% in patients with mild (creatinine clearance, CrCl 50-80 ml/min), moderate (CrCl 30-50 ml/min), and severe (CrCl <30 ml/min) renal impairment and in end-stage renal disease requiring dialysis, respectively.
Izloženost liraglutidu bila je smanjena za 33%, 14%, 27% i 26% u bolesnika s blagim (klirens kreatinina, CrCl 50-80 ml/min), umjerenim (CrCl 30-50 ml/min) i teškim (CrCl <30 ml/min) oštećenjem bubrega, odnosno u završnom stadiju bolesti bubrega gdje je potrebna dijaliza.
When combining liraglutide with metformin, 20.7% of patients reported at least one episode of nausea, and 12.6% of patients reported at least one episode of diarrhoea.
Kad se liraglutid primjenjivao u kombinaciji s metforminom, 20,7% bolesnika prijavilo je barem jednu epizodu mučnine, dok je 12,6% bolesnika prijavilo barem jednu epizodu proljeva.
Over the duration of the phase 3a trials, liraglutide decreased the systolic blood pressure on average of 2.3 to 6.7 mmHg from baseline and compared to active comparator the decrease was 1.9 to 4.5 mmHg.
Tijekom trajanja ispitivanja faze 3a, liraglutid je snizio sistolički krvni tlak za prosječno 2,3 do 6,7 mmHg u odnosu na početnu vrijednost te za 1,9 do 4,5 mmHg u odnosu na aktivni usporedni lijek.
In the LEADER study, delayed gastric emptying was reported three times more frequently in the liraglutide group compared to the placebo group.
U ispitivanju LEADER, odgođeno pražnjenje želuca prijavljeno je tri puta češće u skupini koja je primala liraglutid u usporedbi s placebom.
The patient should be advised to discard the injection needle in accordance with local requirements after each injection and store the pen without an injection needle attached.
Bolesnika treba savjetovati da nakon svakog injiciranja iglu za injiciranje zbrine sukladno lokalnim propisima, a brizgalicu spremi bez pričvršćene igle za injiciranje.
Placebo *Superiority (p<0.01) vs active comparator; **Superiority (p<0.0001) vs active comparator; ***Superiority
*Superiornost (p<0,01) naspram aktivnog usporednog lijeka; **Superiornost (p<0,0001) naspram aktivnog usporednog lijeka; ***Superiornost (p<0,001) naspram aktivnog usporednog lijeka; †Neinferiornost (p<0,0001)
After first use: Store below 30°C or store in a refrigerator (2°C-8°C).
Nakon prve primjene: Čuvati na temperaturi ispod 30°C ili čuvati u hladnjaku (2°C-8°C).
Water for injections
Fenol Voda za injekcije
* human glucagon-like peptide-1 (GLP-1) analogue produced by recombinant DNA technology in Saccharomyces cerevisiae.
*Analog humanog glukagonu sličnog peptida-1 (GLP-1) proizveden tehnologijom rekombinantne
Please dispose of the pen and needle in accordance with local requirements.
Brizgalicu i iglu bacite u otpad sukladno lokalnim propisima.
The small delay of gastric emptying with liraglutide may influence absorption of concomitantly administered oral medicinal products.
Manja odgoda u pražnjenju želuca uz liraglutid mogla bi utjecati na apsorpciju istodobno primijenjenih oralnih lijekova.
Always remove the needle after each injection, and store your pen without a needle attached.
Nakon svakog injiciranja uvijek skinite iglu i spremite svoju brizgalicu bez pričvršćene igle.
>5.5 and <6.7 mmol/l (>100 and <120 mg/dl) 0-2 IUa ≥6.7 mmol/l (≥120 mg/dl)
>5,5 i <6,7 mmol/l (>100 i <120 mg/dl)
Few patients treated with liraglutide reported at least one episode of severe diarrhoea.
Nekoliko bolesnika liječenih liraglutidom prijavilo je najmanje jednu epizodu teškog proljeva.
Thyroid adverse events, such as goitre, have been reported in clinical trials and in particular in patients with pre-existing thyroid disease.
Štetni događaji povezani sa štitnjačom, kao što je struma, prijavljeni su u kliničkim ispitivanjima i osobito u bolesnika s otprije postojećom bolešću štitnjače.
More frequent blood testing to determine the ability of your blood to clot may be required.
Možda će biti potrebne učestalije pretrage krvi kako bi se odredila sposobnost zgrušavanja krvi.
The intra-subject coefficient of variation for liraglutide AUC was 11% following single dose administration.
Intraindividualni koeficijent varijacije za AUC liraglutida bio je 11% nakon primjene jedne doze.
When Victoza is added to a sulfonylurea or insulin, a reduction in the dose of sulfonylurea or insulin should be considered to reduce the risk of hypoglycaemia (see section 4.4).
Kad se Victoza dodaje sulfonilureji ili inzulinu, treba razmotriti smanjenje doze sulfonilureje ili inzulina kako bi se smanjio rizik od hipoglikemije (vidjeti dio 4.4).
Liraglutide exposure was reduced in patients with renal impairment compared to individuals with normal renal function.
Izloženost liraglutidu bila je smanjena u bolesnika s oštećenjem bubrega u usporedbi s pojedincima s normalnom bubrežnom funkcijom.
Animal studies have shown that the transfer of liraglutide and metabolites of close structural relationship into milk is low.
Ispitivanja na životinjama pokazala su nizak stupanj prijelaza liraglutida i strukturno sličnih metabolita u mlijeko.
This reduces the risk of contamination, infection, leakage of liraglutide, blocked needles and inaccurate dosing.
Time se smanjuje rizik od onečišćenja, infekcije, istjecanja liraglutida, začepljenja igala i netočnog doziranja.
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS PRE-FILLED PEN LABEL
PODACI KOJE MORA NAJMANJE SADRŽAVATI MALO UNUTARNJE PAKIRANJE NALJEPNICA NA NAPUNJENOJ BRIZGALICI
Blood glucose self-monitoring is necessary to adjust the dose of sulfonylurea and insulin, particularly when Victoza therapy is started and insulin is reduced.
Samopraćenje razine glukoze u krvi nužno je radi prilagođavanja doze sulfonilureje i inzulina, posebice ako je započeta terapija lijekom Victoza i inzulin je smanjen.
Based on adequate glycaemic control or tolerability, 30% of trial subjects remained on a dose of 0.6 mg, 17% escalated to a dose of 1.2 mg and 53% escalated to a dose of 1.8 mg.
Temeljem adekvatne kontrole glikemije ili podnošljivosti, 30% ispitanika je ostalo na dozi od 0,6 mg, 17% je povećalo dozu na 1,2 mg dok je 53% povećalo dozu na 1,8 mg.
These trials included 3,978 exposed patients with type 2 diabetes mellitus (2,501 patients treated with liraglutide), 53.7% men and 46.3% women, 797 patients (508 treated with liraglutide) were ≥65 years of age and 113 patients (66 treated with liraglutide) were ≥75 years of age.
U ova ispitivanja bilo je uključeno 3978 izloženih bolesnika sa šećernom bolešću tipa 2 (2501 bolesnika liječenih liraglutidom), 53,7% muškaraca i 46,3% žena, 797 bolesnika (508 liječenih liraglutidom) bili su u dobi ≥65 godina i 113 bolesnika (66 liječenih liraglutidom) bili su u dobi
Nervous system disorders
Poremećaji živčanog sustava
Patients treated with liraglutide had a significant decrease in body weight compared to that of patients treated with sitagliptin (-2.9 kg and -3.4 kg vs -1.0 kg, p<0.0001).
U bolesnika liječenih liraglutidom došlo je do značajnog smanjenja tjelesne težine u odnosu na bolesnike liječene sitagliptinom (-2,9 kg i -3,4 kg naspram -1,0 kg, p<0,0001).
Intestinal obstruction
Intestinalna opstrukcija
In a clinical trial with liraglutide as monotherapy, rates of hypoglycaemia reported with liraglutide were lower than rates reported for patients treated with active comparator (glimepiride).
U kliničkom ispitivanju liraglutida u monoterapiji stope hipoglikemije uz liraglutid bile su niže od stopa prijavljenih u bolesnika liječenih aktivnim usporednim lijekom (glimepiridom).
A single dose administration of lisinopril 20 mg with liraglutide resulted in a reduction of lisinopril AUC by 15%; Cmax decreased by 27%.
Primjena jedne doze lizinoprila od 20 mg s liraglutidom rezultirala je smanjenjem AUC lizinoprila za 15%; Cmax se smanjio za 27%.
With continued therapy, the frequency and severity decreased in most patients who initially experienced nausea.
Uz nastavak liječenja, u većine bolesnika koji su u početku osjećali mučninu njezina se učestalost i težina smanjivala.
You can select doses of 0.6 mg, 1.2 mg and 1.8 mg.
Možete odabrati doze od 0,6 mg, 1,2 mg i 1,8 mg.
NAME OF THE MEDICINAL PRODUCT AND ROUTE OF ADMINISTRATION
NAZIV LIJEKA I PUT PRIMJENE LIJEKA
Additional trials were conducted with liraglutide that included 1,901 patients in four unblinded, randomised, controlled clinical trials (including 464, 658, 323 and 177 patients per trial) and one double-blind, randomised, controlled clinical trial in patients with type 2 diabetes mellitus and moderate renal impairment (279 patients).
Provedena su dodatna ispitivanja s liraglutidom u koja je uključen 1901 bolesnik u 4 otvorena randomizirana, kontrolirana klinička ispitivanja (uključujući 464, 658, 323 i 177 bolesnika po ispitivanju) i jedno dvostruko slijepo, randomizirano, kontrolirano ispitivanje u bolesnika sa šećernom bolešću tipa 2 i umjerenim oštećenjem bubrega (279 bolesnika).
Data from clinical trials showed that liraglutide is associated with delayed gastric emptying.
Podaci iz kliničkih ispitivanja pokazuju povezanost liraglutida s odgođenim pražnjenjem želuca.
UNIQUE IDENTIFIER - HUMAN READABLE DATA
JEDINSTVENI IDENTIFIKATOR - PODACI ČITLJIVI LJUDSKIM OKOM PC:
As there is sufficient evidence to conclude on a causal relationship between delayed gastric emptying and liraglutide, delayed gastric emptying should be included as an ADR in section 4.8 of the SmPC with a frequency allocation of ‘uncommon' and in section 4 of the Package Leaflet.
Kako postoji dovoljno dokaza koji ukazuju na uzročnoposljedičnu povezanost između liraglutida i odgođenog pražnjenja želuca, nuspojavu odgođeno pražnjenje želuca s učestalošću „manje često“ treba dodati u dio 4.8 SPC-a i dio 4 upute o lijeku.
Liraglutide has 24-hour duration of action and improves glycaemic control by lowering fasting and postprandial blood glucose in patients with type 2 diabetes mellitus.
Djelovanje liraglutida traje 24 sata i poboljšava regulaciju glikemije snižavanjem glukoze u krvi natašte i nakon obroka u bolesnika sa šećernom bolešću tipa 2.
Simultaneously, liraglutide lowers inappropriately high glucagon secretion, also in a glucose-dependent manner.
Liraglutid istodobno snižava neprimjereno visoko lučenje glukagona, također u ovisnosti od glukoze.
Post-hoc analysis of serious major adverse cardiovascular events (cardiovascular death, myocardial infarction, stroke) from all intermediate and long-term phase 2 and 3 trials (ranging from 26 and up to 100 weeks duration) including 5,607 patients (3,651 exposed to liraglutide), showed no increase in cardiovascular risk (incidence ratio of 0.75 (95% CI 0.35; 1.63)) for liraglutide versus all comparators.
Naknadna analiza ozbiljnih velikih kardiovaskularnih štetnih događaja (smrt uzrokovana kardiovaskularnim događajem, infarkt miokarda, moždani udar) iz svih srednjedugih i dugih ispitivanja 2. i 3. faze (trajanje u rasponu od 26 do 100 tjedana) koja je obuhvatila 5607 bolesnika (3651 izloženih liraglutidu), nije pokazala povećanje kardiovaskularnog rizika (omjer incidencije od 0,75 (95% CI 0,35; 1,63) za liraglutid naspram svih lijekova usporedbe.
- The other ingredients are disodium phosphate dihydrate, propylene glycol, phenol and water for injections.
- Drugi sastojci su natrijev hidrogenfosfat dihidrat, propilenglikol, fenol i voda za injekcije.
• before using Victoza.
• prije nego primijenite lijek Victoza.
The rate of hypoglycaemic episodes (per patient year of exposure) was statistically significantly lower when adding liraglutide compared to adding a single dose of insulin aspart (1.0 vs 8.15; ratio: 0.13; 95% CI: 0.08 to 0.21).
Stopa epizoda hipoglikemija (po izloženosti bolesnik-godina) bila je statistički značajno niža kada je dodan liraglutid u odnosu na dodavanje jedne doze aspart inzulina (1,0 naspram 8,15; omjer: 0,13; 95% CI: 0,08 do
During 24 hours following administration of a single radiolabelled [3H]-liraglutide dose to healthy subjects, the major component in plasma was intact liraglutide.
Biotransformacija Tijekom 24 sata od primjene jedne doze radioaktivno obilježenog [3H]-liraglutida u zdravih ispitanika glavna sastavnica u plazmi bio je nepromijenjeni liraglutid.
Keep the pen cap on in order to protect from light.
Zatvarač držati na brizgalici radi zaštite od svjetlosti.
Greater proportions of patients treated with liraglutide experienced transient nausea vs patients treated with sitagliptin (20.8% and 27.1% for liraglutide vs 4.6% for sitagliptin).
Veći udio bolesnika liječenih liraglutidom imao je prolaznu mučninu naspram bolesnika liječenih sitagliptinom (20,8% i 27,1% za liraglutid naspram 4,6% za sitagliptin).
Substances added to Victoza may cause degradation of liraglutide.
Tvari dodane lijeku Victoza mogu izazvati razgradnju liraglutida.
Be careful not to touch the display with your other fingers or press the dose selector sideways when you inject.
Pazite da ostalim prstima ne dotičete zaslon ili da postrance ne pritisnete izbornik doze tijekom injiciranja, jer bi to moglo blokirati injiciranje.
The mechanism of blood glucose lowering also involves a minor delay in gastric emptying.
Mehanizam snižavanja glukoze u krvi također uključuje i blago odgođeno pražnjenje želuca.
If you forget to use Victoza
Ako ste zaboravili primijeniti lijek Victoza
Liraglutide did not change the overall exposure of atorvastatin to a clinically relevant degree following single dose administration of atorvastatin 40 mg.
Liraglutid nije promijenio ukupnu izloženost atorvastatinu u klinički značajnoj mjeri nakon primjene jedne doze atorvastatina od 40 mg.
The study population included patients ≥65 years (n=4,329) and ≥75 years (n=836) and patients with mild (n=3,907), moderate (n=1,934) or severe (n=224) renal impairment.
Ispitivana populacija uključivala je bolesnike u dobi od ≥65 godina (n=4329) i one u dobi od ≥75 godina (n=836) te bolesnike s blagim (n=3907), umjerenim (n=1934) ili teškim (n=224) oštećenjem bubrega.
Treatment with liraglutide in combination with metformin, metformin and glimepiride, metformin and rosiglitazone or SGLT2i with or without metformin was associated with a sustained weight reduction in the range from 0.86 kg to 2.62 kg compared with placebo.
Liraglutid primijenjen u kombinaciji s metforminom, metforminom i glimepiridom, metforminom i roziglitazonom ili inhibitorom SGLT2 s ili bez metformina bio je povezan s održanim smanjenjem težine u rasponu od 0,86 kg do 2,62 kg u usporedbi s placebom.
Furthermore, hypoglycaemia was common, and very common when liraglutide is used in combination with a sulfonylurea.
Nadalje, hipoglikemija je bila česta, a vrlo česta kad se liraglutid primjenjivao u kombinaciji sa sulfonilurejom.
Dehydration
Dehidracija
The signs include stomach ache, nausea and vomiting.
Znakovi uključuju bolove u želucu, mučninu i povraćanje.
Allergic reactions including urticaria, rash and pruritus have been reported from marketed use of Victoza.
Alergijske reakcije uključujući urtikariju, osip i pruritus prijavljene su nakon stavljanja lijeka Victoza na tržište.
Do not try to select other doses than 0.6 mg, 1.2 mg or 1.8 mg.
Nemojte pokušavati odabrati druge doze osim onih od 0,6 mg, 1,2 mg ili 1,8 mg.
If you stop using Victoza
Ako prestanete primjenjivati lijek Victoza
The HR for liraglutide vs placebo was 0.78 [0.67, 0.92] for time to first nephropathy event and 1.15 [0.87, 1.52] for time to first retinopathy event.
Omjer hazarda za liraglutid u odnosu na placebo iznosio je 0,78 [0,67; 0,92] za vrijeme do prvog događaja nefropatije te 1,15 [0,87; 1,52] za vrijeme do prvog događaja retinopatije.
Turn the dose selector in either direction until 0.6 mg or 1.2 mg lines up with the pointer.
Okrećite izbornik doze u bilo kojem smjeru sve dok se 0,6 mg ili 1,2 mg ne poravna s pokazivačem.
The mean age was 64 years and the mean BMI was 32.5 kg/m².
Srednja vrijednost dobi iznosila je 64 godine, a srednja vrijednost ITM-a 32,5 kg/m2.
At the beginning of the therapy, these gastrointestinal adverse reactions may occur more frequently.
Ove gastrointestinalne nuspojave mogu biti češće na početku liječenja.
The signs include heartburn.
Znakovi uključuju žgaravicu.
Victoza is not recommended for use in patients with severe hepatic impairment (see section 5.2).
Ne preporučuje se primjena lijeka Victoza u bolesnika s teškim oštećenjem jetre (vidjeti dio 5.2).
Increased heart rate
Povećana srčana frekvencija
Larger weight reduction was observed with increasing body mass index (BMI) at baseline.
Smanjenje tjelesne težine bilo je to veće što je početni indeks tjelesne mase (ITM) bio veći.
Patients receiving liraglutide in combination with a sulfonylurea or insulin may have an increased risk of hypoglycaemia (see section 4.8).
U bolesnika koji primaju liraglutid u kombinaciji sa sulfonilurejom ili inzulinom moguć je povećani rizik od hipoglikemije (vidjeti dio 4.8).
In rats, a no observed adverse effect level (NOAEL) was not observed.
Najveća doza bez štetnog učinka (NOAEL) u štakora nije zabilježena.
Treatment with liraglutide produced clinically and statistically significant improvements in glycosylated haemoglobin A1c (HbA1c), fasting plasma glucose and postprandial glucose compared with placebo.
U usporedbi s placebom, liječenje liraglutidom dovelo je do klinički i statistički značajnih poboljšanja u razinama glikoziliranog hemoglobina A1c (HbA1c), glukoze u plazmi natašte i glukoze nakon obroka.
The use of Victoza is not recommended if you have severe liver disease.
Primjena lijeka Victoza ne preporučuje se ako imate tešku bolest jetre.
The use of Victoza is not recommended if you are on dialysis.
Primjena lijeka Victoza ne preporučuje se ako ste na dijalizi.
The risk of hypoglycaemia is low with combined use of basal insulin and liraglutide (1.0 events per patient year, see section 5.1).
Rizik od hipoglikemije je nizak kad se bazalni inzulin i liraglutid primjenjuju u kombinaciji (1,0 događaj po bolesnik-godini, vidjeti dio 5.1).
Turn the dose selector until your needed dose lines up with the pointer (0.6 mg, 1.2 mg or 1.8 mg).
Okrećite izbornik doze sve dok se potrebna doza ne poravna s pokazivačem (0,6 mg, 1,2 mg ili 1,8 mg).
MACE: major adverse cardiovascular event %: proportion in percent of subjects with an event N: number of subjects
FAS: potpuni skup podataka za analizu CI: interval pouzdanosti MACE: veliki kardiovaskularni štetni događaj %: postotni udio ispitanika s događajem N: broj ispitanika
Victoza has no or negligible influence on the ability to drive and use machines.
4.7 Utjecaj na sposobnost upravljanja vozilima i rada sa strojevima Victoza ne utječe ili zanemarivo utječe na sposobnost upravljanja vozilima i rada sa strojevima.
The pharmacokinetics of liraglutide was evaluated in patients with varying degree of hepatic impairment in a single-dose trial.
Farmakokinetika liraglutida procjenjivala se u bolesnika s različitim stupnjevima oštećenja jetre u ispitivanju s jednom dozom lijeka.
In the LEADER trial, severe hypoglycaemic episodes were reported at a lower rate with liraglutide vs placebo (1.0 vs 1.5 events per 100 patient years; estimated rate ratio 0.69 [0.51 to 0.93]) (see section 5.1).
U ispitivanju LEADER stopa prijavljenih epizoda teške hipoglikemije bila je niža uz liraglutid nego uz placebo (1,0 naspram 1,5 događaja na 100 bolesnik-godina; procijenjeni omjer stopa 0,69 [0,51 do 0,93]) (vidjeti dio 5.1).
You may experience nausea, vomiting or diarrhoea.
Može se pojaviti mučnina, povraćanje ili proljev.
A severe form of constipation with additional symptoms such as stomach ache, bloating, vomiting etc.
Teški oblik zatvora s dodatnim simptomima kao što je bol u trbuhu, nadutost, povraćanje itd.
Rate of confirmed hypoglycaemic episodes was higher with liraglutide (0.58 events/patient year) compared to placebo (0.29 events/patient year).
Stopa potvrđenih epizoda hipoglikemija je bila viša uz liraglutid (0,58 događaja/bolesnik godina) u usporedbi s placebom (0,29 događaja/bolesnik godina).
N Mean baseline HbA1c (%)
N Srednja početna vrijednost HbA1c (%)
Novo Nordisk A/S Novo Allé DK-2880 Bagsværd Denmark
DK-2880 Bagsværd
If there is still no drop of liraglutide, change the needle and repeat steps E to G once more.
promijenite iglu i ponovite korake E do G još jednom.
When the pen is empty, carefully dispose of it without a needle attached.
Kad je brizgalica prazna pažljivo je bacite u otpad, bez pričvršćene igle.
Tell your doctor if you are, you think you might be, or are planning to become pregnant.
Ako ste trudni, mislite da biste mogli biti trudni ili planirate imati dijete, obratite se svom liječniku.
In patients treated with insulin prior to a confirmed hypoglycaemic episode the rate was higher with liraglutide (1.82 events/patient year) compared to placebo (0.91 events/patient years).
U bolesnika liječenih inzulinom prije potvrđene epizode hipoglikemije, stopa je bila viša uz liraglutid (1,82 događaja/bolesnik godina) u usporedbi s placebom (0,91 događaja/bolesnik godina).
No dose adjustment is recommended for patients with mild or moderate hepatic impairment.
Ne preporučuje se prilagođavati dozu u bolesnika s blagim ili umjerenim oštećenjem jetre.
You may get hypoglycaemia (low blood sugar) when using Victoza together with a sulfonylurea or insulin, as sulfonylureas and insulin increase the risk of hypoglycaemia.
(niska razina šećera u krvi) kad lijek Victoza primjenjujete zajedno sa sulfonilurejom ili inzulinom, jer sulfonilureja i inzulin povećavaju rizik od hipoglikemije.
Significantly more patients achieved HbA1c below 7% with liraglutide compared with exenatide (54.2% vs 43.4%, p=0.0015).
Značajno veći broj bolesnika postigao je HbA1c ispod 7% s liraglutidom u usporedbi s eksenatidom (54,2% naspram 43,4%, p=0,0015).
Severe hypoglycaemia may occur uncommonly and has primarily been observed when liraglutide is combined with a sulfonylurea (0.02 events/patient year).
Teška hipoglikemija može se pojaviti manje često i to je prije svega zabilježeno kad se liraglutid kombinirao sa sulfonilurejom (0,02 događaja/bolesnik-godina).
Select your dose Always check that the pointer lines up with 0 mg.
Uvijek provjerite je li pokazivač poravnan sa 0 mg.
There was a small increase in the rate of minor hypoglycaemic episodes (0.23 versus 0.03 events per patient years).
Došlo je do malog porasta stope epizoda lakših hipoglikemija (0,23 naspram 0,03 događaja po bolesnik-godini).
Common • Vomiting.
Često • Povraćanje.
When combining liraglutide with a sulfonylurea, 9.1% of patients reported at least one episode of nausea and 7.9% of patients reported at least one episode of diarrhoea.
Kad se liraglutid kombinirao sa sulfonilurejom, 9,1% bolesnika prijavilo je barem jednu epizodu mučnine, dok je 7,9%